Neuroinflammation in Alzheimer’s Disease: Mechanisms, Clinical Implications, and Emerging Therapeutic Strategies

Abstract

Neuroinflammation is increasingly recognized as a pivotal factor in the pathogenesis of Alzheimer’s disease (AD), contributing not only to neurodegeneration but also influencing disease progression and therapeutic outcomes. This review synthesizes current evidence on the mechanisms underlying neuroinflammation in AD, discusses its clinical relevance, and evaluates the implications for diagnosis, management, and emerging therapies. Special focus is placed on the cellular and molecular interplay driving inflammatory responses, risk factors modulating neuroimmune activation, and the translation of recent research into clinical practice. The review aims to provide healthcare professionals and clinicians with an updated, comprehensive perspective to inform diagnosis, risk assessment, and therapeutic strategies in Alzheimer’s disease.

Introduction

Alzheimer’s disease, the most common cause of dementia worldwide, is characterized by progressive cognitive decline, synaptic dysfunction, and neuronal loss. While amyloid-beta (Aβ) plaques and tau neurofibrillary tangles remain hallmark pathological features, accumulating evidence implicates neuroinflammation as a key mediator of disease onset and progression. Understanding neuroinflammation in AD is essential for refining diagnostic approaches, identifying at-risk populations, and developing targeted interventions. This review addresses the epidemiological burden, pathophysiological mechanisms, risk factors, clinical presentation, diagnostic modalities, current management, and recent advances related to neuroinflammation in Alzheimer’s disease.

Epidemiology / Disease Burden

Alzheimer’s disease affects over 55 million individuals globally, with prevalence projected to nearly double by 2050 due to aging populations. The societal and economic impact is profound, with annual costs exceeding hundreds of billions of dollars worldwide. Neuroinflammation is not only a contributing factor to disease pathogenesis but also exacerbates comorbidities and accelerates clinical decline. Epidemiological studies have shown that biomarkers of neuroinflammation, such as increased cerebrospinal fluid (CSF) levels of inflammatory cytokines and microglial activation markers, are associated with faster cognitive deterioration and increased risk of progression from mild cognitive impairment (MCI) to AD.

Pathophysiology

Neuroinflammation in AD arises from a complex interplay between the innate immune system, particularly microglia and astrocytes, and pathological protein accumulation. Microglia, the brain’s resident immune cells, become activated in response to Aβ deposition and tau pathology, releasing proinflammatory cytokines (e.g., IL-1β, IL-6, TNF-α), chemokines, and reactive oxygen species. While acute microglial activation can facilitate Aβ clearance, chronic activation leads to a maladaptive state, perpetuating neuronal damage, synaptic loss, and blood-brain barrier dysfunction. Astrocytes, oligodendrocytes, and peripheral immune cells also participate in the neuroinflammatory milieu. Furthermore, genetic variants in immune-related genes (e.g., TREM2, CD33) modulate susceptibility to neuroinflammation, underscoring the relevance of immune mechanisms in AD pathogenesis.

Risk Factors

Several risk factors amplify neuroinflammatory cascades in Alzheimer’s disease. Aging, the most significant risk factor, is associated with immune senescence and a proinflammatory systemic environment (“inflammaging”). Genetic predispositions, such as APOE ε4 allele carriage and variants in TREM2, increase vulnerability to neuroinflammation. Comorbid conditions particularly metabolic syndrome, diabetes, cardiovascular disease, and traumatic brain injury exacerbate central and peripheral inflammatory responses. Lifestyle factors, including poor diet, physical inactivity, and sleep disturbances, further modulate inflammatory risk. Understanding these factors is critical for early risk stratification and targeted prevention strategies.

Clinical Features

Clinically, neuroinflammation contributes to the heterogeneity and progression of cognitive and neuropsychiatric symptoms in AD. Patients may present with memory impairment, executive dysfunction, apathy, agitation, and neurobehavioral changes. Elevated inflammatory markers in CSF or blood have been correlated with accelerated cognitive decline and increased severity of neuropsychiatric symptoms. Importantly, neuroinflammation may underlie atypical presentations and rapid progression in certain AD phenotypes, highlighting its diagnostic and prognostic value.

Diagnosis

Diagnosing neuroinflammation in AD involves a combination of clinical assessment, neuroimaging, and biomarker evaluation. Advanced neuroimaging techniques, such as PET using radioligands targeting activated microglia (e.g., TSPO tracers), enable in vivo visualization of neuroinflammatory processes. CSF and plasma biomarkers, including cytokines, chemokines, and microglial activation markers (e.g., sTREM2, YKL-40), are under investigation for their diagnostic and prognostic utility. Integrating these biomarkers with established amyloid and tau markers enhances diagnostic specificity and may aid in monitoring therapeutic response.

Treatment & Management

Current management of Alzheimer’s disease remains symptomatic, with cholinesterase inhibitors and memantine offering modest cognitive benefits. However, targeting neuroinflammation represents an emerging therapeutic frontier. Nonsteroidal anti-inflammatory drugs (NSAIDs) have shown inconsistent results in clinical trials, possibly due to late-stage intervention. Immunomodulatory agents, such as monoclonal antibodies targeting Aβ or tau, may indirectly modulate neuroinflammatory responses. Supportive management optimizing cardiovascular health, glycemic control, and lifestyle interventions can attenuate peripheral inflammation and potentially slow disease progression. Multidisciplinary care incorporating neurologists, psychiatrists, and geriatricians is essential for comprehensive management.

Recent Advances / Emerging Therapies

Recent advances in understanding the neuroimmune interface in AD have fueled development of novel therapeutic strategies. Agents targeting microglial activation (e.g., CSF1R inhibitors), inflammasome pathways (e.g., NLRP3 inhibitors), and cytokine signaling are under active investigation. Modulation of gut-brain axis and microbiome-based interventions have shown promise in preclinical models by reducing neuroinflammation. Clinical trials evaluating anti-inflammatory biologics, such as inhibitors of TNF-α or IL-1β, are ongoing. Personalized medicine approaches, leveraging genetic and biomarker profiles, offer the potential for tailored anti-inflammatory therapies in selected patient subgroups.

Guideline Recommendations

Current clinical guidelines emphasize early diagnosis, risk factor modification, and symptomatic management of Alzheimer’s disease. While anti-inflammatory interventions are not yet standard of care, clinicians are encouraged to monitor for comorbidities and implement strategies to reduce systemic inflammation. Ongoing research is likely to inform future guideline updates regarding the use of neuroinflammation-targeted therapies. Multidisciplinary collaboration and patient education remain cornerstones of optimal care.

Conclusion

Neuroinflammation is a central driver of Alzheimer’s disease pathogenesis and progression, offering novel opportunities for risk stratification, biomarker development, and therapeutic intervention. Advances in molecular understanding and translational research are paving the way for targeted strategies to modulate neuroimmune responses and improve clinical outcomes. Continued integration of scientific discovery with clinical practice will be essential to harness the full potential of neuroinflammation-targeted therapies in Alzheimer’s disease.